Public deck

Abivax (ABVX): the ulcerative-colitis readout that has to carry a EUR 530M runway

ABVX is a readout-gated biotech with positive Phase 3 induction data, a much stronger cash position after the 2025 offering, and one big unresolved question: can obefazimod's maintenance data turn runway into a real ulcerative-colitis franchise?